- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03465410
OPTImization of the Dose of tacroliMUS by Bayesian Prediction (OPTIMUS)
OPTIMIZATION of the Dose of tacroliMUS by Bayesian Prediction in Renal Transplant Patients Including Pharmacogenetic Variables
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The results of the study of genetic polymorphisms performed in renal transplant patients at our hospital demonstrated the influence of CYP3A5 * 3 and CYP3A4 * 22 single nucleotide polymorphism (SNPs) on exposure to Tac. From these results, the first population pharmacokinetic model was developed, which included CYP3A5 * 3 and CYP3A4 * 22 polymorphisms as well as hematocrit as explanatory variables of interindividual variability. Based on our population model and using the simulation tool, the percentage of patients reaching the therapeutic target based on Co values within the range of 6-10 ng / mL was determined after being dosed according to the strategy of Conventional dosage empirically according to Co achieved. The simulation of 50 Co values according to the conventional dosage allowed to determine the proportion of patients reaching the therapeutic target in each case and their confidence interval. 40% of the patients did not reach the therapeutic objective. Based on the clusters of the two polymorphisms, the percentages of patients on or below exposed varied according to whether they were slow or fast metabolizers respectively. Due to this high variability in Tac PK, the individualization of the Tac posology was calculated by calculating the initial dose according to the population model previously developed and adjusting the subsequent doses, as a function of the Tac Co through Bayesian approximations with the inclusion of genotyping and Hematocrit, can contribute greatly to achieve optimal exposure to the drug from the start of treatment in the immediate post-transplant and reduce the variability observed in the Co-achieved; This may be particularly important for patients with a slow and rapid metabolizer profile. All of this may contribute to minimizing adverse effects, ensuring greater efficacy in the target population, reducing the risk of acute rejection, and reducing associated costs.
In the present study we intend to incorporate pharmacogenomics for its application in de novo patients, which will allow us to perform a more individualized therapy for each patient based on the values of target Co and the CYP3A5 * 3 and CYP3 A4 * 22 polymorphisms of the patient since The initiation of immunosuppressive therapy and thus improve efficiency and decrease adverse effects.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Hospital Universitari de la Vall d'Hebron
-
L'Hospitalet De Llobregat, Spain
- Hospital Universitari de Bellvitge
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Kidney transplant recipients, from cadaveric and living donor.
- Patients that are going to receive immediate release Tacrolimus (Prograf/Adoport) as part of immunosuppressive treatment.
- Concomitant immunosuppression with Mycophenolate mofetil/Mycophenolic acid and steroids.
- Induction with Basiliximab is permitted.
- Subjects able to provide written informed consent.
- Female subjects of child-bearing potential must have a negative serum pregnancy test and must be practicing an effective, reliable, and medically approved contraceptive regimen during the study.
Exclusion Criteria:
- Subjects treated with drugs that can potentially interfere with Tacrolimus, especially CYP3A4 inhibitors (telaprevir, boceprevir, ritonavir, ketoconazole, voriconazole, itraconazole, telithromycin or clarithromycin) or CYP3A4 inductors (rifampicin or rifabutine).
- Subjects that receive induction treatment with Thymoglobulin or rituximab.
- Subjects participating in another investigational study within 30 days before inclusion.
- Subjects with hepatopathy.
- Subject or donor with a history of any malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin .
- Female subjects who are pregnant or breast feeding.
- Subjects receiving an ABO incompatible kidney.
- Subjects have Donor Specific Antibodies.
- Recipients of an allograft with ischemic cold time > or = 24 hours.
- Subjects with a history of active hepatitis C virus (HCV-RNA positive) and/or hepatitis B virus (DNA-HBV or HBsAg positive) infection.
- Subjects with a history of human immunodeficiency virus (HIV-Ab positive) infection.
- Subjects with psychiatric or physical illness that could interfere with the ability of the subject to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: GROUP I Standard adjustment
Standard dosage of Tacrolimus
|
Immediate release Tacrolimus (Prograf/Adoport)
Other Names:
|
EXPERIMENTAL: GROUP II Bayesian prediction adjustment
Bayesian prediction Tacrolimus dosage
|
Immediate release Tacrolimus (Prograf/Adoport)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tacrolimus plasmatic concentrations measurement
Time Frame: Day 6, 10, 15, 30, 60 and 90 post transplant
|
Concentration measured at day 6, 10, 15, 30, 60 and 90 post transplant and after each Tacrolimus dose adjustment
|
Day 6, 10, 15, 30, 60 and 90 post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to achieve Tacrolimus therapeutic target levels
Time Frame: 90 days
|
Time to achieve Tacrolimus therapeutic target levels within the 90 days post transplant
|
90 days
|
Number of Tacrolimus dose changes to achieve target levels
Time Frame: 90 days
|
Number of Tacrolimus dose changes to achieve target levels
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Núria Lloberas, PhD, Hospital Universitari de Bellvitge
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPTIMUS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on KIDNEY TRANSPLANTATION
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Standard dosage of Tacrolimus
-
Jiangsu Province Centers for Disease Control and...RecruitingCOVID-19 | Pulmonary TuberculosisChina
-
Marmara UniversityUnknown
-
Janssen Research & Development, LLCCompletedPsoriasisFrance, Ukraine, United Kingdom, Germany, Portugal, Canada, Belgium, Russian Federation, Hungary, Sweden
-
China National Center for Cardiovascular DiseasesCompletedAtrial Fibrillation | Valvular Heart DiseaseChina
-
Novartis PharmaceuticalsCompletedLiver TransplantationBelgium, Germany, Italy, United States, Switzerland, Spain, Austria, Czechia, France, Argentina, Finland, Canada
-
Novartis PharmaceuticalsCompletedRenal TransplantationUnited States, Germany, United Kingdom, Belgium, Australia, Hungary, Netherlands, Sweden, Colombia, Argentina, Brazil, Canada, Denmark, Korea, Republic of, Portugal
-
University of FloridaNational Institute on Aging (NIA)CompletedCognitive Impairment | Mobility LimitationUnited States
-
Universidad Autonoma de MadridUnknown
-
Fundación Pública Andaluza Progreso y SaludCompletedChronic Obstructive Pulmonary Disease (COPD)Spain
-
Yale UniversityWithdrawn